journal
https://read.qxmd.com/read/38635076/state-of-open-science-in-cancer-research
#1
JOURNAL ARTICLE
Cristina Rius, Yiming Liu, Andrea Sixto-Costoya, Juan Carlos Valderrama-Zurián, Rut Lucas-Dominguez
PURPOSE: This study has been focused on assessing the Open Science scenario of cancer research during the period 2011-2021, in terms of the derived scientific publications and raw data dissemination. METHODS: A cancer search equation was executed in the Science Citation Index-Expanded, collecting the papers signed by at least one Spanish institution. The same search strategy was performed in the Data Citation Index to describe dataset diffusion. RESULTS: 50,822 papers were recovered, 71% of which belong to first and second quartile journals...
April 18, 2024: Clinical & Translational Oncology
https://read.qxmd.com/read/38627317/efficacy-and-safety-analysis-of-immunotherapy-in-non-small-cell-lung-cancer-patients-with-met-alterations
#2
JOURNAL ARTICLE
Yanhua Wang, Jingwen Wei, Manyi Xu, Jing Xiang, Keda Shao, Yue Hao, Zhengbo Song
BACKGROUND: Mesenchymal epithelial transition factor (MET) is a rare oncologic driver gene, and information on immunotherapy for non-small cell lung cancer (NSCLC) patients with this driver gene is limited. Here we evaluate the efficacy and safety of immune checkpoint inhibitors (ICI) under different therapeutic regimen for NSCLC patients with MET alterations. METHODS: From June 2019 to December 2023, we assessed the efficacy and toxicity of ICIs in 42 NSCLC patients with MET alterations...
April 16, 2024: Clinical & Translational Oncology
https://read.qxmd.com/read/38625495/comparison-of-efficacy-and-safety-of-pd-1-pd-l1-combination-therapy-in-first-line-treatment-of-advanced-nsclc-an-updated-systematic-review-and-network-meta-analysis
#3
JOURNAL ARTICLE
Yanqing Yang, Wei Chen, Lixian Dong, Lian Duan, Pengfei Gao
BACKGROUND: The use of immune checkpoint inhibitors has led to an increase in randomized controlled trials exploring various first-line combination treatment regimens. With the introduction of new PD-1/PD-L1 inhibitors, there are now more clinical options available. For the first time, the AK105 monoclonal antibody Penpulimab, developed in China, was included. The AK105-302 Phase III trial studied the efficacy and safety of Penpulimab combined with chemotherapy in patients with advanced or metastatic squamous NSCLC...
April 16, 2024: Clinical & Translational Oncology
https://read.qxmd.com/read/38625494/exploration-of-efficacy-of-different-therapy-regimens-for-advanced-nsclc-patients-with-kras-mutation-in-the-first-line-treatment
#4
JOURNAL ARTICLE
Ke Wang, Manyi Xu, Yanhua Wang, Chunwei Xu, Yue Hao, Zhengbo Song
PURPOSE: The treatment of the advanced non-small cell lung cancer (NSCLC) with KRAS mutation has been closely paid more attention. The aim of this study is to investigate the efficacy of different first-line regimens in advanced KRAS-mutated non-small cell lung cancer. METHODS: In our retrospective study, we collected patients with advanced NSCLC with KRAS mutation in Zhejiang Cancer Hospital between January 2015 and May 2023. We analyzed the benefit of different first-line therapy according to theraputic methods and the differential effect of the same treatment method among KRAS-mutated subtypes...
April 16, 2024: Clinical & Translational Oncology
https://read.qxmd.com/read/38625493/an-overview-of-current-research-on-cancer-stem-cells-a-bibliometric-analysis
#5
REVIEW
Xueyang Zhang, Wenbo Du, Xizhi Huang, Haoting Zhong, Ning Hu
BACKGROUND: Cancer stem cells (CSCs) represent a potential mechanism contributing to tumorigenesis, metastasis, recurrence, and drug resistance. The objective of this study is to investigate the status quo and advancements in CSC research utilizing bibliometric analysis. METHODS: Publications related to CSCs from 2010 to 2022 were collected from the Web of Science Core Collection database. Various analytical tools including CiteSpace, VOSviewer, Scimago Graphica, and GraphPad Prism were used to visualize aspects such as co-authorship, co-occurrence, and co-citation within CSC research to provide an objective depiction of the contemporary status and developmental trajectory of the CSC field...
April 16, 2024: Clinical & Translational Oncology
https://read.qxmd.com/read/38615292/pancreatic-ductal-adenocarcinoma-exploring-clinicopathological-trends-and-racial-disparities-in-a-comprehensive-u-s-population-based-study
#6
JOURNAL ARTICLE
Abdul Qahar Khan Yasinzai, Bisma Tareen, Katharine Tracy, Nimra Jamil, Marjan Khan, Hafeez Ullah, Muhammad Raza, Amin Ullah Khan, Dauod Arif, Abdul Waheed, Feroze Sidhwa, Subhasis Misra, Nabin Raj Karki, Nagla Abdel Karim, Ludimila Cavalcante, Asad Ullah
INTRODUCTION: Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy about 50% of PDAC are metastatic at presentation. In this study, we evaluated PDAC demographics, annual trend analysis, racial disparities, survival rate, and the role of different treatment modalities in localized and metastatic disease. METHODS: A total of 144,824 cases of PDAC were obtained from the SEER database from 2000 to 2018. RESULTS: The median age was 69 years, with a slightly higher incidence in males (52%) and 80% of all cases were white...
April 14, 2024: Clinical & Translational Oncology
https://read.qxmd.com/read/38609703/prevalence-and-risk-factors-of-thyroid-nodules-in-breast-cancer-women-with-different-clinicopathological-characteristics-a-cross-sectional-study
#7
JOURNAL ARTICLE
Chen-Yu Ma, Xin-Yu Liang, Liang Ran, Lei Hu, Fan-Ling Zeng, Rui-Ling She, Jun-Han Feng, Zhi-Yu Jiang, Zhao-Xing Li, Xiu-Quan Qu, Bai-Qing Peng, Kai-Nan Wu, Ling-Quan Kong
BACKGROUND: Association between breast cancer (BC) and thyroid nodules (TNs) is still unclear. This research was to estimate the prevalence and risk factors of TN in Chinese BC women at initial diagnosis. METHODS: 1731 Chinese early-stage BC women at initial diagnosis underwent thyroid ultrasound and 1:1 age-matched Chinese healthy women underwent health examination in corresponding period were enrolled for analysis. RESULTS: Prevalence of TN and TI-RADS ≥ 4 TN in BC patients (56...
April 12, 2024: Clinical & Translational Oncology
https://read.qxmd.com/read/38602645/exploring-research-progress-in-studying-serum-exosomal-mirna-21-as-a-molecular-diagnostic-marker-for-breast-cancer
#8
REVIEW
Hang Li, Xiao-Jing Tie
Breast cancer is one of the most prevalent malignancies affecting women globally and poses a significant public health challenge. Early clinical detection plays a pivotal role in providing optimal treatment opportunities and favorable prognoses, crucial for reducing breast cancer mortality and enhancing patients' quality of life. Therefore, the timely identification and diagnosis of breast cancer are imperative. Conventional tumor markers, such as carcinoembryonic antigen (CEA) and carbohydrate antigen 15-3 (CA15-3), serve as reliable methods for actively monitoring disease progression and have become a routine auxiliary diagnostic approach in clinical settings...
April 11, 2024: Clinical & Translational Oncology
https://read.qxmd.com/read/38602644/heterogeneity-and-interplay-the-multifaceted-role-of-cancer-associated-fibroblasts-in-the-tumor-and-therapeutic-strategies
#9
REVIEW
Qiaoqiao Liu, Fei Yao, Liangliang Wu, Tianyuan Xu, Jintong Na, Zhen Shen, Xiyu Liu, Wei Shi, Yongxiang Zhao, Yuan Liao
The journey of cancer development is a multifaceted and staged process. The array of treatments available for cancer varies significantly, dictated by the disease's type and stage. Cancer-associated fibroblasts (CAFs), prevalent across various cancer types and stages, play a pivotal role in tumor genesis, progression, metastasis, and drug resistance. The strategy of concurrently targeting cancer cells and CAFs holds great promise in cancer therapy. In this review, we focus intently on CAFs, delving into their critical role in cancer's progression...
April 11, 2024: Clinical & Translational Oncology
https://read.qxmd.com/read/38602643/explainable-and-visualizable-machine-learning-models-to-predict-biochemical-recurrence-of-prostate-cancer
#10
JOURNAL ARTICLE
Wenhao Lu, Lin Zhao, Shenfan Wang, Huiyong Zhang, Kangxian Jiang, Jin Ji, Shaohua Chen, Chengbang Wang, Chunmeng Wei, Rongbin Zhou, Zuheng Wang, Xiao Li, Fubo Wang, Xuedong Wei, Wenlei Hou
PURPOSE: Machine learning (ML) models presented an excellent performance in the prognosis prediction. However, the black box characteristic of ML models limited the clinical applications. Here, we aimed to establish explainable and visualizable ML models to predict biochemical recurrence (BCR) of prostate cancer (PCa). MATERIALS AND METHODS: A total of 647 PCa patients were retrospectively evaluated. Clinical parameters were identified using LASSO regression. Then, cohort was split into training and validation datasets with a ratio of 0...
April 11, 2024: Clinical & Translational Oncology
https://read.qxmd.com/read/38602642/clinical-features-and-treatment-outcomes-of-pd-1-inhibitor-therapy-in-elderly-patients-%C3%A2-%C3%A2-65%C3%A2-years-with-advanced-esophageal-squamous-cell-carcinoma-a-real-world-study
#11
JOURNAL ARTICLE
Yi Yu, Tao Wu, Wei Gan, Can Liu, Ran Zhang, Jinxiu Zheng, Jianping Xiong, Jun Chen, Junhe Li
PURPOSE: This study aims to determine the clinical features and outcomes of PD-1 inhibitor therapy as the initial treatment in patients aged 65 years or older with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC). MATERIALS AND METHODS: The retrospective study conducted a comprehensive analysis of elder patients diagnosed with locally advanced or metastatic ESCC who underwent combined immunochemotherapy in the first affiliated hospital of Nanchang University from January 2019 to January 2023...
April 11, 2024: Clinical & Translational Oncology
https://read.qxmd.com/read/38600340/eclim-sehop-how-to-develop-a-platform-to-conduct-academic-trials-for-childhood-cancer
#12
JOURNAL ARTICLE
Antonio Juan-Ribelles, Francisco Bautista, Adela Cañete, Alba Rubio-San-Simón, Anna Alonso-Saladrigues, Raquel Hladun, Susana Rives, Jose Luís Dapena, Jose María Fernández, Álvaro Lassaletta, Ofelia Cruz, Gemma Ramírez-Villar, Jose Luís Fuster, Cristina Diaz de Heredia, Miguel García-Ariza, Eduardo Quiroga, María Del Mar Andrés, Jaime Verdú-Amorós, Antonio Molinés, Blanca Herrero, Mónica López, Catalina Márquez, María Toboso, Frencisco Lendínez, Jose Gómez Sirvent, María Tallón, Guiomar Rodríguez, Tomás Acha, Lucas Moreno, Ana Fernández-Teijeiro
INTRODUCTION: ECLIM-SEHOP platform was created in 2017. Its main objective is to establish the infrastructure to allow Spanish participation into international academic collaborative clinical trials, observational studies, and registries in pediatric oncology. The aim of this manuscript is to describe the activity conducted by ECLIM-SEHOP since its creation. METHODS: The platform's database was queried to provide an overview of the studies integrally and partially supported by the organization...
April 10, 2024: Clinical & Translational Oncology
https://read.qxmd.com/read/38598002/the-role-of-tet2-in-solid-tumors-and-its-therapeutic-potential-a-comprehensive-review
#13
REVIEW
Wenxin Da, Ziyu Song, Xiaodong Liu, Yahui Wang, Shengjun Wang, Jie Ma
Indeed, tumors are a significant health concern worldwide, and understanding the underlying mechanisms of tumor development is crucial for effective prevention and treatment. Epigenetics, which refers to changes in gene expression that are not caused by alterations in the DNA sequence itself, plays a critical role in the entire process of tumor development. It goes without saying that the effect of methylation on tumors is a significant aspect of epigenetics. Among the methylation modifications, DNA methylation is an important part, which plays a regulatory role in tumor-related genes...
April 10, 2024: Clinical & Translational Oncology
https://read.qxmd.com/read/38598001/effect-of-immune-checkpoint-inhibitors-at-different-treatment-time-periods-on-prognosis-of-patients-with-extensive-stage-small-cell-lung-cancer
#14
JOURNAL ARTICLE
Song Mi, Yunxin Yang, Xin Liu, Shaotong Tang, Ning Liang, Jinyue Sun, Chao Liu, Qidong Ren, Jihong Lu, Pingping Hu, Jiandong Zhang
BACKGROUND: The application of immune checkpoint inhibitors (ICIs) in treating patients with extensive-stage small-cell lung cancer (ES-SCLC) has brought us new hope, but the real-world outcome is relatively lacking. Our aim was to investigate the clinical use, efficacy, and survival benefit of ICIs in ES-SCLC from real-world data analysis. METHODS: A retrospective analysis of ES-SCLC patients was conducted between 2012 and 2022. Progression-free survival (PFS) and overall survival (OS) were assessed between groups to evaluate the value of ICIs at different lines of treatment...
April 10, 2024: Clinical & Translational Oncology
https://read.qxmd.com/read/38594379/evolution-of-radiation-induced-dermatitis-treatment
#15
REVIEW
Deng Guangmei, He Weishan, Liu Wenya, Wu Fasheng, Chen Jibing
Radiation-induced skin damage (RID) is the most prevalent, significant side effect of radiotherapy (RT). Nearly 95% of patients experience moderate to severe skin reactions after receiving radiation therapy. However, criteria for acute radiation dermatitis (ARD) treatment remain unavailable. Topical agents with anti-inflammatory properties may protect the skin and facilitate tissue regeneration in patients with RID. Many of these topical agents function through nuclear factor kappa B pathway regulation. They either reduce the levels of inflammatory factors or elicit anti-inflammatory properties of their own, thus preventing oxidative stress and inflammatory responses and thus enabling RID prevention and management...
April 9, 2024: Clinical & Translational Oncology
https://read.qxmd.com/read/38592638/can-neoadjuvant-systemic-therapy-provide-additional-benefits-for-t1-her2-%C3%A2-breast-cancer-patients-a-subgroup-analysis-based-on-different-high-risk-signatures
#16
JOURNAL ARTICLE
Lidan Chang, Dandan Liu, Xuyan Zhao, Luyao Dai, Xueting Ren, Qian Hao, Peinan Liu, Hao Wu, Xiaobin Ma, Huafeng Kang
INTRODUCTION: Neoadjuvant systemic therapy (NAST) is vital in the management of HER2-positive (HER2+) breast cancer. Nevertheless, the indications for NAST in tumors <2 cm remain controversial. METHOD: A total of 7961 patients were screened from the Surveillance, Epidemiology, and End Result database. Independent prognostic factors were identified using multivariate Cox analysis. Subgroup analyses and Kaplan-Meier analyses were used to simulate whether NAST would provide a survival benefit with different high-risk characteristics...
April 9, 2024: Clinical & Translational Oncology
https://read.qxmd.com/read/38587603/construction-of-a-disulfidptosis-related-glycolysis-gene-risk-model-to-predict-the-prognosis-and-immune-infiltration-analysis-of-gastric-adenocarcinoma
#17
JOURNAL ARTICLE
Zhaohui Liao, Zhengyuan Xie
BACKGROUND: The pattern of cell death known as disulfidptosis was recently discovered. Disulfidptosis, which may affect the growth of tumor cells, represents a potential new approach to treating tumors. Glycolysis affects tumor proliferation, invasion, chemotherapy resistance, the tumor microenvironment (TME), and immune evasion. However, the efficacy and therapeutic significance of disulfidptosis-related glycolysis genes (DRGGs) in stomach adenocarcinoma (STAD) remain uncertain. METHODS: STAD clinical data and RNA sequencing data were downloaded from the TCGA database...
April 8, 2024: Clinical & Translational Oncology
https://read.qxmd.com/read/38587602/efficacy-and-safety-of-a-combination-treatment-of-immune-checkpoint-inhibitors-in-metastatic-breast-cancer-a-systematic-review-and-meta-analysis
#18
JOURNAL ARTICLE
Ying Wang, Yalan Sun, Fang Lu, Xianghong Zhao, Zhenlin Nie, Feng Zhu, Bangshun He
PURPOSE: Immune checkpoint inhibitors (ICIs) in combination with chemotherapy have showed its benefits in clinical studies, and here we conducted a further evaluation on the safety and efficacy of this treatment strategy. METHODS: A systematic literature review was conducted in PubMed, Embase and Cochrane Library to identify clinical studies on ICIs and chemotherapy for metastatic breast cancer. The primary efficacy endpoints were progression-free survival (PFS) and overall survival (OS), and adverse events (AEs) were analyzed...
April 8, 2024: Clinical & Translational Oncology
https://read.qxmd.com/read/38581481/genomic-ancestry-and-cancer-among-latin-americans
#19
JOURNAL ARTICLE
Alejandro Ruíz-Patiño, Leonardo Rojas, Jairo Zuluaga, Oscar Arrieta, Luis Corrales, Claudio Martín, Sandra Franco, Luis Raez, Christian Rolfo, Natalia Sánchez, Andrés Felipe Cardona
Latin American populations, characterized by intricate admixture patterns resulting from the intermingling of ancestries from European, Native American (NA) Asian, and African ancestries which result in a vast and complex genetic landscape, harboring unique combinations of novel variants. This genetic diversity not only poses challenges in traditional population genetics methods but also opens avenues for a deeper understanding of its implications in health. In cancer, the interplay between genetic ancestry, lifestyle factors, and healthcare disparities adds a layer of complexity to the varying incidence and mortality rates observed across different Latin American subpopulations...
April 6, 2024: Clinical & Translational Oncology
https://read.qxmd.com/read/38578538/molecular-profile-in-endometrial-carcinoma-can-we-predict-the-lymph-node-status-a-systematic-review-and-meta-analysis
#20
JOURNAL ARTICLE
Ana Luzarraga Aznar, Vicente Bebia, Natalia Rodriguez Gomez-Hidalgo, Carlos López-Gil, Marta Miguez, Eva Colas, Asunción Pérez-Benavente, Antonio Gil-Moreno, Silvia Cabrera
PURPOSE: Molecular classification of endometrial cancer (EC) has become a promising information to tailor preoperatively the surgical treatment. We aimed to evaluate the rate of lymph node metastases (LNM) in patients with EC according to molecular profile. METHODS: A systematic review and meta-analysis were performed according to PRISMA guidelines by searching in two major electronic databases (PubMed and Scopus), including original articles reporting lymph node metastases according to the molecular classification of EC as categorized in the ESGO-ESMO-ESP guidelines...
April 5, 2024: Clinical & Translational Oncology
journal
journal
41053
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.